Evidence map›Paper›PMID 27000206›Full record

ArticleCancer causes & control : CCC2016

Mortality risk from comorbidities independent of triple-negative breast cancer status: NCI-SEER-based cohort analysis.

Helen Swede, Amna Sarwar, Anil Magge, Dejana Braithwaite, Linda S Cook, David I Gregorio, Beth A Jones, Jessica R Hoag, Lou Gonsalves, Andrew L Salner and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer causes & control : CCC, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Helen SwedeDepartment of Community Medicine and Health Care, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT, 06030-6325, USA. swede@uchc.edu.
Amna SarwarDepartment of Community Medicine and Health Care, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT, 06030-6325, USA.
Anil MaggeDepartment of Community Medicine and Health Care, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT, 06030-6325, USA.
Dejana BraithwaiteDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
Linda S CookDepartment of Epidemiology, Biostatistics and Preventive Medicine, University of New Mexico, Albuquerque, NM, USA.
David I GregorioDepartment of Community Medicine and Health Care, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT, 06030-6325, USA.
Beth A JonesYale School of Public Health, New Haven, CT, USA.
Jessica R HoagDepartment of Community Medicine and Health Care, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT, 06030-6325, USA.
Lou GonsalvesConnecticut Tumor Registry, Connecticut Department of Public Health, Hartford, CT, USA.
Andrew L SalnerHelen & Harry Gray Cancer Center, Hartford Hospital, Hartford HealthCare System, Hartford, CT, USA.
Kristen ZarfosThe Hospital of Central Connecticut, Hartford HealthCare System, Hartford, CT, USA.
Biree AndemariamNew England Sickle Cell Institute, Department of Medicine and Neag Cancer Center, University of Connecticut Health, Farmington, CT, USA.
Richard G StevensDepartment of Community Medicine and Health Care, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT, 06030-6325, USA.
Alicia G DuganNew England Sickle Cell Institute, Department of Medicine and Neag Cancer Center, University of Connecticut Health, Farmington, CT, USA.
Mellisa PensaDepartment of Occupational and Environmental Medicine, Yale School of Medicine, New Haven, CT, USA.
Jessica A BrockmeyerDepartment of Community Medicine and Health Care, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT, 06030-6325, USA.

Funding

Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI DAVID L RIMM · 1985 to 2026
$85.0M
CCR NIH HHS HHSN261201300011CNCI NIH HHS HHSN261201300019CNCI NIH HHS HHSN261201300019INCI NIH HHS HHSN261201300091CNCI NIH HHS P30 CA016359
6 · The paper itself

Abstract

purposeA comparatively high prevalence of comorbidities among African-American/Blacks (AA/B) has been implicated in disparate survival in breast cancer. There is a scarcity of data, however, if this effect persists when accounting for the adverse triple-negative breast cancer (TNBC) subtype which occurs at threefold the rate in AA/B compared to white breast cancer patients.

methodsWe reviewed charts of 214 white and 202 AA/B breast cancer patients in the NCI-SEER Connecticut Tumor Registry who were diagnosed in 2000-2007. We employed the Charlson Co-Morbidity Index (CCI), a weighted 17-item tool to predict risk of death in cancer populations. Cox survival analyses estimated hazard ratios (HRs) for all-cause mortality in relation to TNBC and CCI adjusting for clinicopathological factors.

resultsAmong patients with SEER local stage, TNBC increased the risk of death (HR 2.18, 95 % CI 1.14-4.16), which was attenuated when the CCI score was added to the model (Adj. HR 1.50, 95 % CI 0.74-3.01). Conversely, the adverse impact of the CCI score persisted when controlling for TNBC (Adj. HR 1.49, 95 % CI 1.29-1.71; per one point increase). Similar patterns were observed in SEER regional stage, but estimated HRs were lower. AA/B patients with a CCI score of ≥3 had a significantly higher risk of death compared to AA/B patients without comorbidities (Adj. HR 5.65, 95 % CI 2.90-11.02). A lower and nonsignificant effect was observed for whites with a CCI of ≥3 (Adj. HR 1.90, 95 % CI 0.68-5.29).

conclusionscomorbidities at diagnosis increase risk of death independent of TNBC, and AA/B patients may be disproportionately at risk.

Indexed as

ComorbidityAdultAgedBlack or African AmericanCohort StudiesConnecticutFemaleHumansMiddle AgedPrevalenceProportional Hazards ModelsRisk FactorsSurvival AnalysisTriple Negative Breast NeoplasmsWhite PeopleBreast cancerCancer survival disparityCharlson Co-Morbidity IndexCo-morbidityTNBC

Identifiers

PMID27000206
PMCPMC5591028

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.